Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
JCEM Case Reports|March 16, 2026
Progression from Stage 1 to Stage 3 Type 1 Diabetes Characterized by HypoglycemiaAakash Nagarapu, Jamie L FeltonImmunohorizons|July 15, 2021
Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?Jamie L FeltonBiomolecules|May 4, 2026
Type I Interferons as Contextual Regulators of B-Cell Tolerance in Type 1 DiabetesMebrahtu G Tedla, Jamie L FeltonBiomedicines|January 9, 2021
B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 DiabetesJamie L Felton, Holly Conway, Rachel H BonamiJournal of Immunology (Baltimore, Md. : 1950)|June 29, 2018
Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 DiabetesJamie L Felton, Damian Maseda, Rachel H Bonami, et al.Journal of Surgical Education|July 20, 2026
The Rise of Productivity Culture: Assessing Trends in Scholarly Output Among Medical Students Applying to General SurgeryTyler Lackland, Benjamin Pointer, Seraphim Le, et al.Diabetes Care|April 24, 2025
Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic UnderstandingLaura M Jacobsen, Jamie L Felton, Brandon M Nathan, et al.Journal of Biomedical Materials Research. Part B, Applied Biomaterials|June 26, 2024
Combined regenerative rehabilitation improves recovery following volumetric muscle loss injury in a rat modelDavid Johnson, Connor Tobo, Jeffrey Au, et al.The Journal of Clinical Endocrinology and Metabolism|April 2, 2025
Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care ProvidersSteven B Leichter, Jamie L Felton, Cristy Geno Rasmussen, et al.Diabetologia|October 13, 2021
HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participantsJamie L Felton, David Cuthbertson, Megan Warnock, et al.Pageof 3